AVITA Medical shareholders approve director fee pool increase, equity grants, and warrant issuance

9. Approval of the Issuance of Warrants (Proposal 14): Stockholders approved, for the purpose of ASX Listing Rule 7.1 (and all other purposes), the issuance of a warrant or warrants covering up to 650,000 shares of Common Stock, with a term of ten years (the “Warrants”), to Perceptive Credit Holdings V, LP (“Perceptive”), pursuant to the credit agreement between the Company and Perceptive, dated January 13, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 9,322,532 1,769,627 609,746 3,890,542

5. Issuance of Securities to Dr. Michael Tarnoff (Proposal 8) : Stockholders approved the initial grant comprised of 26,250 restricted stock units and 19,063 stock options, to Dr. Michael Tarnoff, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,791,498 2,433,367 477,040 3,890,542

10. Approval of the Issuance of Equity Securities (Proposal 15): Stockholders approved as a special resolution, for the purpose of ASX Listing Rule 7.1A (which allows the Company to seek stockholder approval to issue an additional 10% over the annual listing limit of 15% of its issued capital in a consecutive 12-month period) and all other purposes, the issue of Equity Securities (as defined in ASX Listing Rule 19.2) up to such additional 10% of the issued capital (at the time of issuance) of the Company (as calculated in accordance with ASX Listing Rule 7.1A.2). The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,947,195 2,223,106 531,604 3,890,542

7. Advisory Vote to Approve Compensation of Named Executive Officers (Proposal 12) : Stockholders voted in favor of the non-binding advisory vote to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,918,272 2,202,213 581,420 3,890,542

3. Increase the maximum aggregate annual cash fee pool from which the non-executive Directors of the Company may be paid (Proposal 3): Stockholders approved, for the purposes of ASX Listing Rule 10.17 and section 2.10 of the Company’s Amended and Restated Bylaws (and for all other purposes), an increase to the aggregate annual cash fee pool from which non-executive directors of the Company may be paid for their services from a maximum of US$750,000 per annum to a maximum of US$900,000 per annum. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,582,602 2,710,656 408,647 3,890,542

At the Annual Meeting, the Company’s stockholders voted on all the proposals summarized in the Proxy Statement, as set forth below: 1. Election of Directors (Proposal 1) : All seven directors named in the Proxy Statement were elected to serve on the Company’s Board of Directors with the following votes: Name Votes For Votes Withheld Broker Non-Votes Jan Stern Reed 10,902,991 798,914 3,890,542 Professor Suzanne Crowe 10,979,194 722,711 3,890,542 Jeremy Curnock Cook 10,700,424 1,001,481 3,890,542 Robert McNamara 10,962,888 739,017 3,890,542 Dr. Michael Tarnoff 11,011,908 689,997 3,890,542 Joseph Woody 10,977,874 724,031 3,890,542 Cary Vance 11,176,792 525,113 3,890,542

8. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation (Proposal 13) : Stockholders voted in favor of the non-binding advisory vote to set the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 9,545,151 924,743 650,252 581,759 3,890,542

2. Appointment of Independent Auditor (Proposal 2) : The stockholders ratified the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions 14,962,654 255,151 374,642

4. Issuance of Securities to Non-Executive Directors (Proposals 4 - 7, 9 & 11) : Stockholders approved the annual grants comprised of 22,214 restricted stock units and 16,133 stock options, to each of the following non-executive directors, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding these proposals were as follows: Votes For Votes Against Abstentions Broker Non-Votes Professor Suzanne Crowe 8,869,562 2,411,009 421,334 3,890,542 Jeremy Curnock Cook 8,722,810 2,544,450 434,645 3,890,542 Robert McNamara 8,818,589 2,449,386 433,930 3,890,542 Jan Stern Reed 8,841,764 2,434,253 425,888 3,890,542 Dr. Michael Tarnoff 8,774,530 2,458,787 468,588 3,890,542 Joseph Woody 8,830,204 2,446,817 424,884 3,890,542

6. Issuance of Securities to Joseph Woody (Proposal 10) : Stockholders approved the initial grant comprised of 40,547 restricted stock units and 29,446 stock options, to Mr. Joseph Woody, in accordance with the terms and conditions set out in the Proxy Statement. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,863,312 2,395,376 443,217 3,890,542